CN110663948A - 一种具有增强免疫力作用的保健品及其制备方法 - Google Patents
一种具有增强免疫力作用的保健品及其制备方法 Download PDFInfo
- Publication number
- CN110663948A CN110663948A CN201911138523.1A CN201911138523A CN110663948A CN 110663948 A CN110663948 A CN 110663948A CN 201911138523 A CN201911138523 A CN 201911138523A CN 110663948 A CN110663948 A CN 110663948A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- ginseng
- placing
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 19
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 241000222336 Ganoderma Species 0.000 claims abstract description 13
- 241001416980 Paecilomyces hepiali Species 0.000 claims abstract description 13
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 10
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 10
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 9
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- JBGYSAVRIDZNKA-NKECSCAMSA-N (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@]3(C)O[C@H](CC3)C(C)(C)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O JBGYSAVRIDZNKA-NKECSCAMSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000357439 Epinephelus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000863031 Lysobacter Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- -1 triterpene compounds Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
一种具有增强免疫力作用的保健品及其制备方法，涉及保健品领域。该保健品由以下重量份的原料组成：蝙蝠蛾拟青霉菌粉20‑25份、灵芝30‑35份、西洋参20‑25份、三七10‑15份。经提取浓缩干燥等工序，制成干膏后与辅料混合制粒填充即得。本发明工艺流程简洁，原料配比科学合理，提高免疫力功能明确。
Description
本发明涉及保健品领域，具体涉及一种具有增强免疫力作用的保健品及其制备方法。
技术背景
现代社会激烈的生存竞争及环境变化决定了在非常长的时期内仍会有大量人群处于亚健康状态，导致免疫力下降，通过保健食品改善免疫功能、提高免疫力，就成为养生保健的重要途径之一。我国已批准的以蛹虫草为主要原料的保健食品只有9个，主要为胶囊剂及口服液，功能均为增强人体免疫力，这对于满足我国免疫力低下人群的日常保健需求来说，是远远不够的。
本发明采用蝙蝠蛾拟青霉菌粉、灵芝、西洋参、三七为原料各原料均具有增强免疫力的保健功能。
蝙蝠蛾拟青霉菌粉富含腺苷、多糖等活性物质，不仅含量丰富且比例适当，有效增强人体体质，全面提高了免疫机能和抗疲劳能力。
灵芝主要含麦角、甾醇、真菌溶酶菌、酸性蛋白质、水溶性蛋白质、多种氨基酸、灵芝醇、灵芝酸、赤芝酸、多肽、生物碱及水溶性多糖类、三萜化合物等成分。对神经系统有抑制作用，循环系统有降压和加强心脏收缩力的作用，对呼吸系统有祛痰作用，此外，还有护肝、提高免疫功能，抗菌等作用。
西洋参中主要成分为人参皂苷，已分离出的5种皂苷分别为：人参皂苷R0、Rb1、Rg1、Re和假人参皂苷F11。具有抗疲劳、抗氧化、抗应激、抑制血小板聚集、降低血液凝固性的作用，对心血管系统有保护作用；增强机体抗应激能力；增强免疫功能；保护红细胞膜；抗利尿等作用。
三七主要含人参皂苷Rg1、槲皮素、乙酸、丁香烯、人参皂苷Re、亮氨酸、β-谷固醇-D-葡萄糖苷、人参炔三醇、三七皂苷等12种单体皂苷及止血成分田七氨酸。可增强免疫功能，保护肝功能，抗肿瘤，延缓衰老，降血糖，抗炎，调节物质代谢，促进生长。
发明内容
本发明提供一种具有增强免疫力作用的保健品及其制备方法。
本发明主要包括下述重量份的原料：
蝙蝠蛾拟青霉菌粉15-25份、灵芝25-35份、西洋参15-25份、三七5-15份。
其制备方法包括以下步骤：
(1)将三七粉碎并过25目筛；
(2)取灵芝、西洋参饮片和已粉碎的三七粉，加6～12倍的水提取2～3次，每次2.0小时，过滤；
(3)将滤液合并并减压浓缩，温度为60℃～80℃，并浓缩至相对密度为1.3(60℃测)的稠膏，备用；
(4)将稠膏，置托盘中，真空干燥，温度为60℃～80℃，得干膏，备用；
(5)取真空干燥后干膏，置于粉碎机中，粉碎并过筛，得中药提取物粉，备用。将过100目筛的蝙蝠蛾拟青霉菌粉、中药提取物粉和淀粉置于混合机中，混匀，至混合物颜色均匀，用颗粒机制成颗粒，整粒后加硬脂酸镁进行总混，再进行胶囊填充，包装即得。
附图说明
图1为本发明提取工艺图
图2为本发明制剂工艺图
具体实施方式
为了使本发明实现的技术手段、创作特征易于理解，下面结合具体实施例，进一步阐述本发明。
实施例1.
一种具有增强免疫力作用的保健品包含以下重量份的原料：蝙蝠蛾拟青霉菌粉15份、灵芝25份、西洋参15份、三七5份。
(1)将三七粉碎并过25目筛；
(2)取灵芝、西洋参饮片和已粉碎的三七粉，加6倍的水提取2次，每次2.0小时，过滤；
(3)将滤液合并并减压浓缩，温度为60℃，并浓缩至相对密度为1.3(60℃测)的稠膏，备用；
(4)将稠膏，置托盘中，真空干燥，温度为60℃，得干膏，备用；
(5)取真空干燥后干膏，置于粉碎机中，粉碎并过筛，得中药提取物粉，备用。将过100目筛的蝙蝠蛾拟青霉菌粉、中药提取物粉和淀粉置于混合机中，混匀，至混合物颜色均匀，用颗粒机制成颗粒，整粒后加硬脂酸镁进行总混，再进行胶囊填充，包装即得。
实施例2.
一种具有增强免疫力作用的保健品包含以下重量份的原料：蝙蝠蛾拟青霉菌粉20份、灵芝30份、西洋参20份、三七10份。
(1)将三七粉碎并过25目筛；
(2)取灵芝、西洋参饮片和已粉碎的三七粉，加8倍的水提取3次，每次2.0小时，过滤；
(3)将滤液合并并减压浓缩，温度为70℃，并浓缩至相对密度为1.3(60℃测)的稠膏，备用；
(4)将稠膏，置托盘中，真空干燥，温度为70℃，得干膏，备用；
(5)取真空干燥后干膏，置于粉碎机中，粉碎并过筛，得中药提取物粉，备用。将过100目筛的蝙蝠蛾拟青霉菌粉、中药提取物粉和淀粉置于混合机中，混匀，至混合物颜色均匀，用颗粒机制成颗粒，整粒后加硬脂酸镁进行总混，再进行胶囊填充，包装即得。
实施例3.
一种具有增强免疫力作用的保健品包含以下重量份的原料：蝙蝠蛾拟青霉菌粉25份、灵芝35份、西洋参25份、三七15份。
(1)将三七粉碎并过25目筛；
(2)取灵芝、西洋参饮片和已粉碎的三七粉，加12倍的水提取3次，每次2.0小时，过滤；
(3)将滤液合并并减压浓缩，温度为80℃，并浓缩至相对密度为1.3(60℃测)的稠膏，备用；
(4)将稠膏，置托盘中，真空干燥，温度为80℃，得干膏，备用；
(5)取真空干燥后干膏，置于粉碎机中，粉碎并过筛，得中药提取物粉，备用。将过100目筛的蝙蝠蛾拟青霉菌粉、中药提取物粉和淀粉置于混合机中，混匀，至混合物颜色均匀，用颗粒机制成颗粒，整粒后加硬脂酸镁进行总混，再进行胶囊填充，包装即得。
实施例4
通过动物实验，并根据人的口服用量设置低、中、高剂量组及阴性对照组，将小鼠分为对应的低、中、高剂量组及阴性对照组，阴性对照组使用同体积的纯化水灌胃，其他三组分别按要求给对应组的动物进行灌胃，连续灌胃30天。采用ConA诱导小鼠淋巴细胞转化实验(MTT法)及NK细胞活性测定法、耳肿胀法、小鼠碳廓清实验、小鼠腹腔巨噬细胞吞噬鸡血红细胞等实验方法进行实验，最后得出结果见表一、表二。
表一 小鼠免疫功能各项实验结果(
mg/kg BW)
表二 小鼠碳廓清实验、腹腔巨噬细胞吞噬鸡血红细胞与NK细胞活性实验结果(mg/kg BW)
由表一、表二实验结果说明本发明提供的保健品能提高小鼠的脾淋巴细胞增值，提高小鼠抗体生成细胞数，促进小鼠碳廓清吞噬能力，本发明提供的保健品具有增强免疫力的功能。
本发明工艺流程简洁，原料配比科学合理，生产工艺成熟稳定、质量可靠、服用方便，提高免疫力功能明确。
以上为本发明的优选实施方式，对于本领域的技术人员来说，在不脱离本发明的范围前提下，本发明还会有各种变化和改进，这些变化和改进也应纳入本发明的保护范围。
Claims (2)
1.一种具有增强免疫力作用的保健品及其制备方法，其特征在于包含以下重量份的原料：
蝙蝠蛾拟青霉菌粉15-25份、灵芝25-35份、西洋参15-25份、三七5-15份。
2.权利要求1所述的制备方法，其特征包含以下步骤：
(1)将三七粉碎并过25目筛。
(2)取灵芝、西洋参饮片和已粉碎的三七粉，加6～12倍的水提取2～3次，每次2.0小时，过滤。
(3)将滤液合并并减压浓缩，温度为60℃～80℃，并浓缩至相对密度为1.3(60℃测)的稠膏，备用。
(4)将稠膏，置托盘中，真空干燥，温度为60℃～80℃，得干膏，备用。
(5)取真空干燥后干膏，置于粉碎机中，粉碎并过筛，得中药提取物粉，备用。将过100目筛的蝙蝠蛾拟青霉菌粉、中药提取物粉和淀粉置于混合机中，混匀，至混合物颜色均匀，用颗粒机制成颗粒，整粒后加硬脂酸镁进行总混，再进行胶囊填充，包装即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911138523.1A CN110663948A (zh) | 2019-11-20 | 2019-11-20 | 一种具有增强免疫力作用的保健品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911138523.1A CN110663948A (zh) | 2019-11-20 | 2019-11-20 | 一种具有增强免疫力作用的保健品及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110663948A true CN110663948A (zh) | 2020-01-10 |
Family
ID=69087877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911138523.1A Pending CN110663948A (zh) | 2019-11-20 | 2019-11-20 | 一种具有增强免疫力作用的保健品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110663948A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114081911A (zh) * | 2021-10-18 | 2022-02-25 | 李远枚 | 一种生命玄线修复综合疗法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130028968A1 (en) * | 2011-07-29 | 2013-01-31 | Andy Teh-An Huang | Compositions and methods to relieve chronic diseases symptoms |
| CN105124578A (zh) * | 2015-09-06 | 2015-12-09 | 威海御膳坊生物科技有限公司 | 一种保健食品 |
| CN108066384A (zh) * | 2016-11-08 | 2018-05-25 | 郑州桂仁医药科技有限公司 | 一种具有增强免疫力功能的中药制剂及其制备方法 |
-
2019
- 2019-11-20 CN CN201911138523.1A patent/CN110663948A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130028968A1 (en) * | 2011-07-29 | 2013-01-31 | Andy Teh-An Huang | Compositions and methods to relieve chronic diseases symptoms |
| CN105124578A (zh) * | 2015-09-06 | 2015-12-09 | 威海御膳坊生物科技有限公司 | 一种保健食品 |
| CN108066384A (zh) * | 2016-11-08 | 2018-05-25 | 郑州桂仁医药科技有限公司 | 一种具有增强免疫力功能的中药制剂及其制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114081911A (zh) * | 2021-10-18 | 2022-02-25 | 李远枚 | 一种生命玄线修复综合疗法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101152007B (zh) | 一种保健品组合物及其制备方法 | |
| CN102308988B (zh) | 一种具有增强人体免疫功能的石斛保健品 | |
| CN1762236B (zh) | 一种能增强人体免疫力的保健食品及其制备方法 | |
| CN103285231B (zh) | 一种用于糖尿病辅助治疗的药物组合物及其制法 | |
| CN103740566B (zh) | 一种刺梨药酒及其制作方法 | |
| CN110694048A (zh) | 覆盆子参杞片及制备方法 | |
| CN112021572A (zh) | 一种醒酒保肝保健食品及其制备方法 | |
| CN101884783B (zh) | 一种含有麦麸多肽的抗疲劳中药及其制备方法 | |
| WO2020173172A1 (zh) | 减肥片的组成及其制备方法 | |
| CN110663948A (zh) | 一种具有增强免疫力作用的保健品及其制备方法 | |
| CN106901326A (zh) | 一种树舌灵芝全活性物质的制备与应用 | |
| CN111109596A (zh) | 一种增强免疫力的保健品及其制备方法 | |
| CN106581166A (zh) | 一种具有抗疲劳功效的食品、保健品或药物组合物 | |
| CN111357891A (zh) | 一种含洋蓟人参的植物饮品及其制备方法 | |
| CN1718220A (zh) | 一种健胃消食片的鉴别方法 | |
| CN110025709B (zh) | 一种苓术山药散的制备方法及其应用 | |
| CN109394799B (zh) | 含灵芝萃取物的天然药物组合物及其制备方法和应用 | |
| CN108567854A (zh) | 参灵口服液及其制备方法 | |
| CN108578578B (zh) | 一种具有降血脂功效的药物组合物及其制备方法 | |
| CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
| CN109674942A (zh) | 一种降血脂药物组合物、制备方法及其应用 | |
| CN107467654B (zh) | 一种海带海参复合提取物及其制备方法和应用 | |
| WO2010037255A1 (zh) | 一种人参绞股蓝复方制剂在制备调节血脂、血糖的药物中的用途 | |
| CN110585321A (zh) | 一种用于防治贫血的中药组合物及其制备方法与应用 | |
| CN107136510A (zh) | 一种提高免疫力保健食品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200110 |